My watch list  

Synthetic biology

The term synthetic biology has long been used to describe an approach to biology that attempts to integrate (or "synthesize") different areas of research in order to create a more holistic understanding of life. More recently the term has been used in a different way, signaling a new area of research that combines science and engineering in order to design and build ("synthesize") novel biological functions and systems. The present article discusses the term in this latter meaning.



History of the term

In 1974, the Polish geneticist Waclaw Szybalski introduced the term "synthetic biology"[1], writing: Let me now comment on the question "what next". Up to now we are working on the descriptive phase of molecular biology. ... But the real challenge will start when we enter the synthetic biology phase of research in our field. We will then devise new control elements and add these new modules to the existing genomes or build up wholly new genomes. This would be a field with the unlimited expansion potential and hardly any limitations to building "new better control circuits" and ..... finally other "synthetic"organisms, like a "new better mouse". ... I am not concerned that we will run out exciting and novel ideas, ... in the synthetic biology, in general. When in 1978 the Nobel Prize in Physiology or Medicine was awarded to Arber, Nathans and Smith for the discovery of restriction enzymes, Waclaw Szybalski wrote in an editorial comment in the journal Gene: The work on restriction nucleases not only permits us easily to construct recombinant DNA molecules and to analyze individual genes, but also has led us into the new era of synthetic biology where not only existing genes are described and analyzed but also new gene arrangements can be constructed and evaluated.[2]


Biologists are interested in learning more about how natural living systems work. One simple, direct way to test our current understanding of a natural living system is to build an instance (or version) of the system in accordance with our current understanding of the system. Michael Elowitz's early work on the Repressilator [1] is one good example of such work. Elowitz had a model for how gene expression should work inside living cells. To test his model, he built a piece of DNA in accordance with his model, placed the DNA inside living cells, and watched what happened. Slight differences between observation and expectation highlight new science that may be well worth doing. Work of this sort often makes good use of mathematics to predict and study the dynamics of the biological system before experimentally constructing it. A wide variety of mathematical descriptions have been used with varying accuracy, including graph theory, Boolean networks, ordinary differential equations, stochastic differential equations, and Master equations (in order of increasing accuracy). Good examples include the work of Adam Arkin, Jim Collins and Alexander van Oudenaarden. See also the PBS Nova special on artificial life.


Biological systems are physical systems that are made up of chemicals. Around 100 years ago, the science of chemistry went through a transition from studying natural chemicals to trying to design and build new chemicals. This transition led to the field of synthetic chemistry. In the same tradition, some aspects of synthetic biology can be viewed as an extension and application of synthetic chemistry to biology, and include work ranging from the creation of useful new biochemicals to studying the origins of life. Eric Kool's group at Stanford, Steven Benner's group at Florida, Carlos Bustamante's group at Berkeley, and Jack Szostak's group at Harvard are good examples of this tradition.


Engineers view biology as a technology. Synthetic Biology includes the broad redefinition and expansion of biotechnology, with the ultimate goals of being able to design and build engineered biological systems that process information, manipulate chemicals, fabricate materials and structures, produce energy, provide food, and maintain and enhance human health and our environment. A good example of these technologies include the work of Chris Voigt, who redesigned the Type III secretion system used by Salmonella typhimurium to secrete spider silk proteins, a strong elastic biomaterial, instead of its own natural infectious proteins. One aspect of Synthetic Biology which distinguishes it from conventional genetic engineering is a heavy emphasis on developing foundational technologies that make the engineering of biology easier and more reliable. Good examples of engineering in Synthetic Biology include the pioneering work of Tim Gardner and Jim Collins on an engineered genetic toggle switch, the Registry of Standard Biological Parts, and the International Genetically Engineered Machine competition (iGEM).


Re-writers are Synthetic Biologists who are interested in testing the idea that since natural biological systems are so complicated, we would be better off re-building the natural systems that we care about, from the ground up, in order to provide engineered surrogates that are easier to understand and interact with. Re-writers draw inspiration from refactoring, a process sometimes used to improve computer software. Drew Endy and his group have done some preliminary work on re-writing (e.g., Refactoring Bacteriophage T7). Oligonucleotides harvested from a photolithographic or inkjet manufactured DNA chip combined with DNA mismatch error-correction allows inexpensive large-scale changes of codons in genetic systems to improve gene expression or incorporate novel amino-acids (see George Church's lab synthetic cell projects, Anthony Forster's lab and the Minimal Cell Project (MCP)). As in the T7 example above, this favors a synthesis-from-scratch approach.

Human practices: Emerging social, ethical, legal challenges

In addition to numerous bioscientific challenges, the vast potential of synthetic biology to play a formative role in contemporary human life raises new questions for bioethics, biosecurity, biosafety, health, energy and intellectual property. To date considerable focus has been given to the so-called dual-use challenge. For example, while the study of synthetic biology can lead to more efficient ways to produce cures (e.g. against malaria), it may also lead to synthesis or redesign of harmful pathogens (e.g., smallpox). In addition, scientists, funders, policymakers, ethicists and others have recognized challenges presented by a post 9/11 political milieu. A new range of potentially malicious actors and actions (i.e., terrorists/terrorism) must now be taken into account by those seeking to govern scientific domains; and the internet and other new media provide global access to technological know-how and scientific knowledge. Such global access cannot be addressed using existing models of nation-specific regulation. (New Scientist, November 12, 2005). Some detailed suggestions for licensing and monitoring the various phases of gene and genome synthesis are beginning to appear. There is also an ongoing, comprehensive, and open discussion of so-called “societal issues” online at OpenWetWare.

Recently, efforts have been made to think beyond the “societal issues” model of ethics, politics, and science in relation to synthetic biology. This effort refuses the established convention of imagining society outside of and downstream of scientific practices, such that bioethics is assigned the task of limiting the negative impact of science on society. By contrast recent approaches focus on the integral and mutually formative relations among scientific and other human practices. These human practices approaches attempt to invent ongoing and regular forms of collaboration among synthetic biologists, ethicists, political analysts, funders, human scientists and civil society activists. To date collaborative work on “governance” or “society” or “ethics” in relation to synthetic biology has largely consisted either of intensive, short term meetings, aimed at producing guidelines or regulations, or standing committees whose purpose is limited to protocol review or rule enforcement. Such work has proven valuable in identifying the ways in which synthetic biology intensifies already-known challenges in rDNA technologies. However, these forms are not suited to identifying new challenges as they emerge. An example of efforts to develop ongoing collaboration is the Human Practices component of the Synthetic Biology Engineering Research Center (SynBERC), an NSF funded collaboration among a number of leading research universities. In Europe, the multi-partner project SYNBIOSAFE is investigating the biosafety, biosecurity and ethical aspects of synthetic biology.

Key enabling technologies

There are several key enabling technologies that are critical to the growth of synthetic biology.


Synthetic biologists make use of DNA sequencing in their work in several ways. First, large-scale genome sequencing efforts continue to provide a wealth of information on naturally occurring organisms. This information provides a rich substrate from which synthetic biologists can construct parts and devices. Second, synthetic biologists use sequencing to verify that they fabricated their engineered system as intended. Third, fast, cheap and reliable sequencing can also facilitate rapid detection and identification of synthetic systems and organisms.


A critical limitation in synthetic biology today is the time and effort expended during fabrication of engineered genetic sequences. To speed up the cycle of design, fabrication, testing and redesign, synthetic biology requires more rapid and reliable de novo DNA synthesis and assembly of fragments of DNA.

In 2002 researchers at SUNY Stony Brook succeeded in synthesizing the 7741 base poliovirus genome from its published sequence, producing the first synthetic organism. This took about two years of painstaking work.[3] In 2003 the 5386 bp genome of the bacteriophage Phi X 174 was assembled in about two weeks.[4] In 2006, the same team, at the J. Craig Venter Institute, has announced and patented plans to produce a synthetic genome of a novel minimal bacterium, Mycoplasma laboratorium.[5]

In 2007 it was reported that several companies were offering the synthesis of genetic sequences up to 2000 bp long, for a price of about $1 per base pair and a turnaround time of less than two weeks.[6]


Models inform the design of engineered biological systems by allowing synthetic biologists to better predict system behavior prior to fabrication. Synthetic biology will benefit from better models of how biological molecules bind substrates and catalyze reactions, how DNA encodes the information needed to specify the cell and how multi-component integrated systems behave.


Precise and accurate quantitative measurements of biological systems are crucial to improving understanding of biology. Such measurements often help to elucidate how biological systems work and provide the basis for model construction and validation. Differences between predicted and measured system behavior can identify gaps in understanding and explain why synthetic systems don't always behave as intended. Technologies which allow many parallel and time-dependent measurements will be especially useful in synthetic biology. Microscopy and flow cytometry are examples of useful measurement technologies.

See also


  1. ^ Waclaw Szybalski, In Vivo and in Vitro Initiation of Transcription, Page 405. In: A. Kohn and A. Shatkay (Eds.), Control of Gene Expression, pp. 23-24, and Discussion pp. 404-405 (Szybalski's concept of Synthetic Biology), 411-412, 415 - 417. New York: Plenum Press, 1974
  2. ^ Gene 1978, 4, p 181
  3. ^ Couzin J (2002). "Virology. Active poliovirus baked from scratch". Science 297 (5579): 174-5. doi:10.1126/science.297.5579.174b. PMID 12114601.
  4. ^ Smith, Hamilton O.; Clyde A. Hutchison, Cynthia Pfannkoch, J. Craig Venter (2003-12-23). "Generating a synthetic genome by whole genome assembly: {phi}X174 bacteriophage from synthetic oligonucleotides". Proceedings of the National Academy of Sciences 100 (26): 15440-15445. doi:10.1073/pnas.2237126100. Retrieved on 2007-10-08.
  5. ^ Wade, Nicholas. "Scientists Transplant Genome of Bacteria", The New York Times, 2007-06-29. Retrieved on 2007-12-28. 
  6. ^ Pollack, Andrew. "How Do You Like Your Genes? Biofabs Take Orders", The New York Times, 2007-09-12. Retrieved on 2007-12-28. 


  • Video interviews with synthetic biology experts, NGOs and funding institutions


  • Amyris Biotechnologies
  • ATG:biosynthetics
  • Blue Heron Biotechnology, Inc.
  • CODA Genomics
  • Codon Devices, Inc.
  • DNA 2.0
  • febit synbio gmbh
  • LS9, Inc.
  • Sloning Biotechnology
  • Synthetic Genomics, Inc.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Synthetic_biology". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE